UNSPSC 51386601: Alcohol/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386601 Alcohol/hydrocortisone is a Commodity code under which state and local governments procure pharmaceutical products, naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products to support community health, pharmacy benefit, and public health emergency-response initiatives. The issuing bodies span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions. Recent solicitations show procurement of naloxone for opioid overdose response, generic pharmaceuticals distributed through authorized wholesalers under cooperative purchasing agreements, and therapeutic pharmacy programs involving direct-to-manufacturer prescription fulfillment models. Vendors must hold current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), maintain FDA-compliant products with specified shelf-life requirements, carry comprehensive insurance including commercial general liability of $2,000,000 to $5,000,000 per occurrence, and pass E-Verify employment eligibility verification.

Activity appears concentrated in Florida and the Upper Midwest, with multistate coordination through cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to its Community Health Building, with responses due July 26, 2023; the contract includes a two-year initial term with one-year renewal option and FEMA-potential funding. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers, with proposal responses due March 26, 2026 and contract awards effective July 1, 2026; pricing weighting is 75 percent, with vendors paying 3 percent administrative fees and subject to performance penalties of $200 to $1,500 per violation. Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct contracting relationships outside traditional pharmacy benefit manager and group purchasing organization channels.